The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
Addressing individual treatment goals is crucial to patient satisfaction1-3
|
The numbers*
|
The impact
|
|---|---|
| Of patients with psoriasis, 62% have scalp symptoms 22% have nail symptoms | Though they represent a small portion of BSA, scalp and nail symptoms significantly impact QoL |
| 43% of patients with psoriasis identified pruritus as the most bothersome symptom of their disease | Reduction in pruritus is correlated with improvements in QoL |
| 22% of patients with psoriasis and a BSA of ≤3 palms rated their disease as "severe" | BSA is not the only factor that contributes to patient perception of disease severity |
| Up to 35% of patients with psoriasis develop PsA | PsA leads to disability and significantly impacts QoL |
| In more than 80% of patients, psoriasis affects their overall emotional state and interferes with their enjoyment of life | The emotional burden of psoriasis remains high, and dissatisfaction with current treatment is prevalent |
| Patients with moderate psoriasis are more likely to report dissatisfaction with treatment3 | |
PATIENTS WITH PSORIASIS IDENTIFY SUBSTANTIAL
NEEDS THAT GO BEYOND SKIN CLEARANCE4†
For patients with moderate plaque psoriasis,
traditional systemic therapy may not be enough
aData from the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, a population-based survey of 3,426 patients in North American and Europe.
bBased on the national survey data collected by the National Psoriasis Foundation in the United States. Survey data were collected from randomly sampled patients with psoriasis and psoriatic arthritis in the US population from a database of more than 76,000 patients with psoriatic disease.
*Based on the Multinational Assessment of Psoriasis and Psoriatic Arthritis survey, a survey of 3,426 patients with psoriasis and psoriatic arthritis, the WHO 2016 Global Report on Psoriasis and the National Psoriasis Foundation Survey (2003-2011), a survey of 5,604 psoriasis and psoriatic patients in the US.
†Cross-sectional study of patients undergoing treatment for dermatological diagnoses (N = 500), including psoriasis vulgaris. Results are based on responses to the Patient Benefit Questionnaire and include only those patients with psoriasis (n = 50). Percentages reflect patients indicating moderate or high benefit on a scale from 0 (not at all) to 4 (strongly).
BSA, body surface area; QoL, quality of life.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
